Clinical Research

Investigator-Initiated Clinical Research

CD38 antibody Isatuximab for treatment of Monoclonal Gammopathy of renal significance (NCT04614558).
PI: Divaya Bhutani, MD

CD38 antibody Isatuximab during Autologous Stem Cell Collection and Transplantation Period in patients with Multiple Myeloma and Lymphoma.
PI: Divaya Bhutani, MD

Non-invasive MRD assessment using liquid biopsy and functional imaging (NCT05625971).
PI: Rajshekar Chakraborty, MD

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis (NCT05451771).(link is external and opens in a new window)
PI: Rajshekhar Chakraborty, MD

Industry-Sponsored Clinical Research

Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma.(link is external and opens in a new window)
PI: Suzanne Lentzsch, MD, PhD

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis.(link is external and opens in a new window)
PI: Divaya Bhutani, MD

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis.(link is external and opens in a new window)
PI: Divaya Bhutani, MD